News

According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective

The acquisition of KaNDy Therapeutics will allow Bayer to expand its drug development pipeline in women’s healthcare. The deal also allows KaNDy Therapeutics to secure potential milestone payments

Appili is expanding its Phase 2 clinical trial into the U.S. to evaluate the safety and efficacy of favipiravir tablets in controlling outbreaks following exposure to COVID-19 in

All patients initially required mechanical ventilation, and all recovered and survived with narsoplimab treatment. A manuscript detailing the results of the study has been accepted for publication in

Presently, Veklury is being administered to hospitalised patients with severe Covid-19 under an emergency use authorisation (EUA) issued by the FDA. According to Gilead Sciences, the latest drug

Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.

Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead. In March, Pfizer launched

Lampit, an antiprotozoal medication will be available in a new, dividable tablet that can be split on the scored lines by hand. According to prescribing instructions, the tablet

The deal between the firms allows Takeda Pharmaceutical to undertake the local production and commercialisation of NVX‑CoV2373 in Japan, which will be backed by funding from the Japanese